ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:May 9, 2018
End Date:February 9, 2025
Contact:Brian A Van Tine, M.D., Ph.D.

Use our guide to learn which trials are right for you!

A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1)
expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with
a decreased overall survival. Using the extracellular arginine depleting enzyme PEGylated
arginine deiminase (ADI-PEG20), an extracellular arginine depleting enzyme, the investigators
demonstrated ADI-PEG20 induces a prosurvival metabolic reprogramming in ASS1-deficient
sarcomas that redirects glucose into the serine/folate pathway directing the carbons from
glucose into pyrimidine biosynthesis, thus sensitizing cells to death by the pyrimidine
antimetabolite gemcitabine by using metabolomics. The synthetic lethality was increased by
the addition of docetaxel. Therefore a phase II clinical trial of ADI with gemcitabine and
docetaxel, a standard second line therapy for soft tissue sarcoma will be conducted to
determine if the clinical benefit rate of gemcitabine and docetaxel is improved by the
metabolic changes induced by ADI-PEG20

Inclusion Criteria:

- Histologically or cytologically confirmed grade 2 or 3 soft tissue sarcoma that is
unresectable or metastatic that would be standardly treated with gemcitabine or
gemcitabine and docetaxel. Prior surgery for primary or metastatic disease after
chemotherapy following a response is allowed.

- Measurable disease defined as lesions that can be accurately measured in at least one
dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by
chest x-ray, or ≥ 10 mm with calipers by clinical exam.

- Treated with at least one line of systemic therapy in the palliative setting or with
neoadjuvant or adjuvant chemotherapy within the prior six months. The allowable window
between treatments is 21 days for chemotherapy or a TKI, or 5 ½ half-lives for a TKI
(whichever is shorter), 21 days and progression by CT for immunotherapy, 21 days for
RT, 21 days for surgery, or 28 days for an investigational agent.

- At least 18 years of age.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Normal bone marrow and organ function as defined below:

- Leukocytes ≥ 3,000/mcL

- Absolute neutrophil count ≥ 1,500/mcl

- Platelets ≥ 100,000/mcl

- Total bilirubin ≤ 2 x institutional upper limit of normal (IULN)

- AST(SGOT)/ALT(SGPT) ≤ 3 x IULN (or ≤ 5 x IULN if liver metastases are present)

- Creatinine ≤ 1.5 x IULN OR

- Creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels
above institutional normal

- Serum uric acid ≤ 8 mg/dL (with or without medication control)

- Women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control, abstinence) prior to study entry and for
the duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she must inform her treating physician

- Ability to understand and willingness to sign an IRB approved written informed consent
document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

- A history of other high grade malignancy ≤ 5 years previous. Exceptions include basal
cell or squamous cell carcinoma of the skin which were treated with local resection
only or carcinoma in situ of the cervix, or other tumors discussed with the study PI

- Currently receiving any other investigational agents.

- Prior treatment with ADI-PEG 20, gemcitabine, or docetaxel

- Known brain metastases. Patients with known brain metastases must be excluded from
this clinical trial because of their poor prognosis and because they often develop
progressive neurologic dysfunction that would confound the evaluation of neurologic
and other adverse events.

- A history of allergic reactions attributed to compounds of similar chemical or
biologic composition to ADI-PEG 20, gemcitabine, pegylated compounds, or other agents
used in the study.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- History of seizure disorder not related to underlying cancer.

- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
pregnancy test within 14 days of study entry.

- Known HIV-positivity on combination antiretroviral therapy because of the potential
for pharmacokinetic interactions with the study treatment. In addition, these patients
are at increased risk of lethal infections when treated with marrow-suppressive
therapy. Appropriate studies will be undertaken in patients receiving combination
antiretroviral therapy when indicated.
We found this trial at
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Brian A Van Tine, M.D., Ph.D.
Phone: 314-362-5817
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Saint Louis, MO
Click here to add this to my saved trials
Palo Alto, California 34304
Principal Investigator: Nam Bui, M.D.
Phone: 713-412-8721
Palo Alto, CA
Click here to add this to my saved trials
Santa Monica, California 90403
Principal Investigator: Sant P Chawla, M.D.
Phone: 310-552-9999
Santa Monica, CA
Click here to add this to my saved trials